ArticleInternational journal of molecular sciences2018
Combined Gastric and Colorectal Cancer Screening-A New Strategy.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- A targeted DNA methylation method for detecting gastrointestinal cancer in circulating cell-free DNA.iScience · 2026Article
- Screening for and surveillance of premalignant conditions of the stomach.Best practice & research. Clinical gastroenterology · 2025Review
- Combined Breast and Lung Cancer Screening Among Dual-Eligible Women: A Descriptive Study.The Journal of surgical research · 2025Article
- Review
- A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When?Cancers · 2023Review
- [Helicobacter pylori-New aspects of forthcoming guidelines].Der Internist · 2022Review
- Incorporating Helicobacter pylori Infection: A Novel Model for Predicting Advanced Colorectal Neoplasia.HelicobacterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur aim was to evaluate the feasibility of a serological assessment of gastric cancer risk in patients undergoing colonoscopy in countries with low-to-moderate incidence rates.
methodsSerum samples were prospectively collected from 453 patients (>50 years old) undergoing colonoscopies. Of these, 279 (61.6%) also underwent gastroscopy to correlate the results for serum pepsinogen I and II (sPG-I and sPG-II), sPG-I/II ratio, and anti-
results
conclusionsThe assessment of serum pepsinogen allows the identification of patients at increased risk of gastric cancer. A prevention strategy of combining a screening colonoscopy with a serological screening for preneoplastic gastric changes should be considered in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.